

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Simcere Pharmaceutical Group Limited

先聲藥業集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 2096)

CHANGE OF JOINT COMPANY SECRETARY

The board (the “**Board**”) of directors (“**Directors**”) of Simcere Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Ms. WONG Wai Ling (“**Ms. Wong**”) has tendered her resignation as a joint company secretary of the Company (the “**Joint Company Secretary**”) with effect from March 25, 2026.

Ms. Wong has confirmed that she has no disagreement with the Board and there is no matter in relation to her resignation that needs to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board further announces that Ms. MAK Po Man Cherie (“**Ms. Mak**”) has been appointed as the Joint Company Secretary with effect from March 25, 2026. Mr. WAN Yushan (“**Mr. Wan**”) will remain as the other Joint Company Secretary. The Stock Exchange has confirmed that Mr. Wan has satisfied the requirements under Rule 3.28 of the Listing Rules of the Stock Exchange and is qualified to act as the company secretary of the Company.

The biographical details of Ms. Mak and Mr. Wan are set out as follows:

Ms. Mak is the Vice President of SWCS Corporate Services Group (Hong Kong) Limited. She has worked for various professional firms and listed companies in Hong Kong, with over 20 years of experience in the fields of audit, accounting, corporate finance, compliance and corporate secretarial matters. Ms. Mak obtained a Master of Corporate Governance degree from The Hong Kong Polytechnic University in 2017. She was admitted as an associate member of The Hong Kong Chartered Governance Institute and The Chartered Governance Institute in 2017, a member of the Hong Kong Institute of Certified Public Accountants in 2003, and a fellow member of the Association of Chartered Certified Accountants in 2006.

Mr. Wan is an executive Director, the chief financial officer of the Company and one of the Joint Company Secretaries. He is primarily responsible for financial, legal and compliance management, formulating financial strategies and in charge of the process and information business of the Group.

Mr. Wan has over 23 years of experience with the Group where he has accumulated knowledge and skills required in the financial management of the Group. Mr. Wan joined the Group in May 2000 and has assumed various positions successively since then, including the financial controller, general manager of financial department, vice president and chief financial officer. On November 19, 2019, Mr. Wan was officially appointed as an executive Director and the chief financial officer of the Company. He has also been the director of several subsidiaries of the Company including, among others, Hainan Sincere Pharmaceutical Co., Ltd. (海南先聲藥業有限公司) since July 2011 and Sincere Pharmaceutical Co., Ltd. (先聲藥業有限公司) since July 2017.

Mr. Wan obtained a bachelor's degree in biochemistry from Nanjing University (南京大學) in June 1992 and a master's degree in management (majoring in accounting) from Nanjing University (南京大學) in June 1999. Mr. Wan was admitted as a non-practicing member of Jiangsu Institute Certified Public Accountants (江蘇省註冊會計師協會) in November 2009.

The Board would like to take this opportunity to express its gratitude to Ms. Wong for her contribution to the Company during her tenure and to welcome Ms. Mak on her new appointment.

By order of the Board
Sincere Pharmaceutical Group Limited
Mr. REN Jinsheng
Chairman and Executive Director

Hong Kong, March 25, 2026

As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director, Mr. TANG Renhong, Mr. WAN Yushan and Ms. WANG Xi as the executive Directors; Mr. SONG Ruilin, Mr. WANG Jianguo, Mr. WANG Xinhua and Mr. SUNG Ka Woon as the independent non-executive Directors.